{"cluster": 20, "subcluster": 52, "abstract_summ": "Objective This study aimed to compare two recently-authorized rapid tests, Cepheid Xpert Xpress SARS-CoV-2 and Abbott ID Now SARS-CoV-2, to the Roche cobas SARS-CoV-2 assay for samples with low, medium, and high viral concentrations.This study compared two recently-authorized rapid tests, Cepheid Xpert Xpress SARS-CoV-2 and Abbott ID Now SARS-CoV-2 to the Roche cobas SARS-CoV-2 assay.Here, we provide support for the adoption of sample pooling with the point-of-care Cepheid Xpert\u00ae Xpress SARS-CoV-2 molecular assay.RESULTS: Xpert Xpress SARS-CoV-2 point of care test showed equal performance compared to routine in-house testing with a limit of detection (LOD) of 8.26 copies/mL. Other seasonal respiratory viruses were not detected.We present here the results of comparisons between Abbott ID NOW COVID-19 and Cepheid Xpert Xpress SARS-CoV-2 using nasopharyngeal swabs transported in viral transport media and comparisons between Abbott ID NOW COVID-19 and Cepheid Xpert Xpress SARS-CoV-2 using nasopharyngeal swabs transported in viral transport media for Cepheid and dry nasal swabs for Abbott ID NOW.", "title_summ": "Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2.Performance of Abbott ID NOW COVID-19 rapid nucleic acid amplification test in nasopharyngeal swabs transported in viral media and dry nasal swabs, in a New York City academic institutionComparison of the NeuMoDX, Diasorin Simplexa, Cepheid and Roche CDC SARS-CoV 2 EUA assays using nasopharyngeal/nasal swabs in universal transport media (UTM) and sputum and tracheal aspiratesTest Agreement Between Roche Cobas 6800 and Cepheid GeneXpert Xpress SARS-CoV-2 Assays at High Cycle Threshold RangesRecommendations for sample pooling on the Cepheid GeneXpert\u00ae system using the Cepheid Xpert\u00ae Xpress SARS-CoV-2 assayComparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2Multi-center evaluation of cepheid xpert\u00ae xpress SARS-CoV-2 point-of-care test during the SARS-CoV-2 pandemicPerformance of Abbott ID NOW COVID-19 rapid nucleic acid amplification test in nasopharyngeal swabs transported in viral media and dry nasal swabs, in a New York City academic institution.Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Test.Evaluation of the COVID19 ID NOW EUA assay.", "title_abstract_phrases": "Test Agreement Between Roche Cobas 6800 and Cepheid GeneXpert Xpress SARS-CoV-2 Assays at High Cycle Threshold RangesThe SARS-CoV-2 pandemic has changed the face of the globe and upended the daily lives of billions.Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Test.Objective This study aimed to compare two recently-authorized rapid tests, Cepheid Xpert Xpress SARS-CoV-2 and Abbott ID Now SARS-CoV-2, to the Roche cobas SARS-CoV-2 assay for samples with low, medium, and high viral concentrations.This study compared two recently-authorized rapid tests, Cepheid Xpert Xpress SARS-CoV-2 and Abbott ID Now SARS-CoV-2 to the Roche cobas SARS-CoV-2 assay.Here, we provide support for the adoption of sample pooling with the point-of-care Cepheid Xpert\u00ae Xpress SARS-CoV-2 molecular assay."}